在159872例癌症患者中的真实世界患病率支持肿瘤突变负荷高（TMB-H）在定义转移性实体瘤以使用帕博利珠单抗治疗方面的临床实用性。 - Suppr | 超能文献

相似文献

1

Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.在159872例癌症患者中的真实世界患病率支持肿瘤突变负荷高（TMB-H）在定义转移性实体瘤以使用帕博利珠单抗治疗方面的临床实用性。

Ann Oncol. 2021 Sep;32(9):1193-1194. doi: 10.1016/j.annonc.2021.05.805. Epub 2021 May 31.

2

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.回复：D. 法布里齐奥等人所著的《159872例癌症患者的真实世界患病率支持肿瘤突变负荷高（TMB-H）在定义转移性实体瘤以指导帕博利珠单抗治疗方面的临床应用》

Ann Oncol. 2021 Sep;32(9):1194-1197. doi: 10.1016/j.annonc.2021.06.017. Epub 2021 Jun 21.

3

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.T 细胞炎症基因表达谱、程序性死亡配体 1 表达和肿瘤突变负担可预测帕博利珠单抗治疗 20 种癌症患者的疗效：KEYNOTE-028。

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

4

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。

Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.

5

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.转移性实体瘤患者接受免疫检查点抑制剂治疗的真实世界临床病理观察：肯塔基癌症登记处的分析。

Cancer Med. 2021 Mar;10(6):2054-2062. doi: 10.1002/cam4.3802. Epub 2021 Feb 22.

6

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.获批后一年接受纳武利尤单抗和帕博利珠单抗治疗的真实世界转移性非小细胞肺癌患者的特征。

Oncologist. 2018 Mar;23(3):328-336. doi: 10.1634/theoncologist.2017-0353. Epub 2018 Jan 9.

7

Immunogenicity of pembrolizumab in patients with advanced tumors.帕博利珠单抗治疗晚期肿瘤患者的免疫原性。

J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4.

8

A real-world data of Immune checkpoint inhibitors in solid tumors from India.印度实体瘤免疫检查点抑制剂的真实世界数据。

Cancer Med. 2021 Mar;10(5):1525-1534. doi: 10.1002/cam4.3617. Epub 2021 Feb 16.

9

The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No.美国食品药品监督管理局（FDA）批准帕博利珠单抗用于肿瘤突变负荷（TMB）>10个突变/Mb的患者：这是一个明智的决定吗？不是。

Ann Oncol. 2020 Sep;31(9):1112-1114. doi: 10.1016/j.annonc.2020.07.001. Epub 2020 Aug 5.

10

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗微卫星高度不稳定实体瘤。

Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20.

引用本文的文献

1

Clinical and Technical Validation of OncoIndx Assay-A Comprehensive Genome Profiling Assay for Pan-Cancer Investigations.OncoIndx检测的临床与技术验证——一种用于泛癌研究的综合基因组分析检测

Cancers (Basel). 2024 Oct 8;16(19):3415. doi: 10.3390/cancers16193415.

2

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.基因组特征对新诊断卵巢癌免疫治疗的影响：来自 IMagyn050 随机临床试验的生物标志物分析。

Clin Cancer Res. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032.

3

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.